[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals (NasdaqGS:REGN) Gains Conditional EC Approval For Lynozyfic In Multiple Myeloma",
    "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) experienced a 7% price increase over the past week, coinciding with the European Commission's regulatory approval of Lynozyfic for relapsed and refractory multiple myeloma, which may have bolstered investor confidence despite broader uncertainties. This positive development for Regeneron came while the market overall saw a similar upward trajectory of 7%. Additionally, the company's efforts to expand its manufacturing capacity with FUJIFILM Diosynth...",
    "url": "https://finnhub.io/api/news?id=feaf830d123b768fb3164a830cb565f07e24d918d61293e248377e6fd1dd1531",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745861592,
      "headline": "Regeneron Pharmaceuticals (NasdaqGS:REGN) Gains Conditional EC Approval For Lynozyfic In Multiple Myeloma",
      "id": 134131502,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) experienced a 7% price increase over the past week, coinciding with the European Commission's regulatory approval of Lynozyfic for relapsed and refractory multiple myeloma, which may have bolstered investor confidence despite broader uncertainties. This positive development for Regeneron came while the market overall saw a similar upward trajectory of 7%. Additionally, the company's efforts to expand its manufacturing capacity with FUJIFILM Diosynth...",
      "url": "https://finnhub.io/api/news?id=feaf830d123b768fb3164a830cb565f07e24d918d61293e248377e6fd1dd1531"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=36fc3ddd293dba02a427324dd6fac71a9c8c768f7062152eeb1e2c45c0572f56",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745858580,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 134152108,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=36fc3ddd293dba02a427324dd6fac71a9c8c768f7062152eeb1e2c45c0572f56"
    }
  },
  {
    "ts": null,
    "headline": "Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?",
    "summary": "Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.",
    "url": "https://finnhub.io/api/news?id=0baf42e6b97681e5c18609832f6de6672ad5abe20f1451bccc8d6c2b17fbbd65",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745856480,
      "headline": "Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?",
      "id": 134130904,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.",
      "url": "https://finnhub.io/api/news?id=0baf42e6b97681e5c18609832f6de6672ad5abe20f1451bccc8d6c2b17fbbd65"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron expands US manufacturing with $3B Fujifilm partnership",
    "summary": "The deal nearly doubles the pharmaceutical giant’s domestic capacity as demand for biologics surges.",
    "url": "https://finnhub.io/api/news?id=730d2a30269403b83c7e1861dd577823685c294560de7c80b3f3f927eaacdfdf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745840280,
      "headline": "Regeneron expands US manufacturing with $3B Fujifilm partnership",
      "id": 134131504,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The deal nearly doubles the pharmaceutical giant’s domestic capacity as demand for biologics surges.",
      "url": "https://finnhub.io/api/news?id=730d2a30269403b83c7e1861dd577823685c294560de7c80b3f3f927eaacdfdf"
    }
  },
  {
    "ts": null,
    "headline": "Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma",
    "summary": "Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to patients who face cycles of relapse and remission TARRYTOWN, N.Y., April 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) has granted conditional marketing approval of Lynozyfic™ (linvoseltamab) to treat adults with relapsed and",
    "url": "https://finnhub.io/api/news?id=a01f055b9198ec799c862be36dd599aaf0013bb7a0a03fa1dadf176095088f1f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745838060,
      "headline": "Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma",
      "id": 134115468,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to patients who face cycles of relapse and remission TARRYTOWN, N.Y., April 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) has granted conditional marketing approval of Lynozyfic™ (linvoseltamab) to treat adults with relapsed and",
      "url": "https://finnhub.io/api/news?id=a01f055b9198ec799c862be36dd599aaf0013bb7a0a03fa1dadf176095088f1f"
    }
  },
  {
    "ts": null,
    "headline": "EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease",
    "summary": "Initial real-world data from nearly 40,000 EYLEA HD patients will provide early insights on effectiveness of EYLEA HD in everyday clinical practice New indirect comparisons will evaluate EYLEA HD and faricimab on measures of efficacy, dosing frequency and potential economic benefits in patients with wet age-related macular degeneration and diabetic macular edema TARRYTOWN, N.Y., April 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the upcoming present",
    "url": "https://finnhub.io/api/news?id=f816d05c4bb8e9d61cc57d754dfd4a6cd6833666b42b221fb53e845600e288ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745838000,
      "headline": "EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease",
      "id": 134115469,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Initial real-world data from nearly 40,000 EYLEA HD patients will provide early insights on effectiveness of EYLEA HD in everyday clinical practice New indirect comparisons will evaluate EYLEA HD and faricimab on measures of efficacy, dosing frequency and potential economic benefits in patients with wet age-related macular degeneration and diabetic macular edema TARRYTOWN, N.Y., April 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the upcoming present",
      "url": "https://finnhub.io/api/news?id=f816d05c4bb8e9d61cc57d754dfd4a6cd6833666b42b221fb53e845600e288ab"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron (REGN) Reports Earnings Tomorrow: What To Expect",
    "summary": "Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings tomorrow morning. Here’s what you need to know.",
    "url": "https://finnhub.io/api/news?id=dfa733db31f993378a04b936623ed12002b5f575e4bbdce023842b4e04fdfab4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745823880,
      "headline": "Regeneron (REGN) Reports Earnings Tomorrow: What To Expect",
      "id": 134115470,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings tomorrow morning. Here’s what you need to know.",
      "url": "https://finnhub.io/api/news?id=dfa733db31f993378a04b936623ed12002b5f575e4bbdce023842b4e04fdfab4"
    }
  }
]